TY  - JOUR
AU  - Pescoller, Julia
AU  - Dewenter, Anna
AU  - Dehsarvi, Amir
AU  - Steward, Anna
AU  - Frontzkowski, Lukas
AU  - Zhu, Zeyu
AU  - Roemer-Cassiano, Sebastian N
AU  - Palleis, Carla
AU  - Hirsch, Fabian
AU  - Wagner, Fabian
AU  - de Bruin, Hannah
AU  - Rauchmann, Boris Stephan
AU  - Perneczky, Robert
AU  - Gnoerich, Johannes
AU  - Malpetti, Maura
AU  - Ossenkoppele, Rik
AU  - Schöll, Michael
AU  - Levin, Johannes
AU  - Höglinger, Günter U
AU  - Brendel, Matthias
AU  - Franzmeier, Nicolai
TI  - Cortical tau deposition promotes atrophy in connected white matter regions in Alzheimer's disease.
JO  - Brain
VL  - 148
IS  - 12
SN  - 0006-8950
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DZNE-2025-01345
SP  - 4359 - 4371
PY  - 2025
AB  - In Alzheimer's disease (AD), fibrillar tau pathology is a key driver of neurodegeneration and cortical atrophy. Yet, emerging evidence suggests that tau aggregates also contribute to white matter (WM) damage. Specifically, physiological tau stabilizes intra-axonal microtubules, whereas hyperphosphorylated tau disrupts microtubule integrity, with ensuing intraneuronal tau aggregation, neuronal disconnection and axonal degeneration. Therefore, we investigated whether cortical tau promotes atrophy in connected WM regions in AD. To this end, we included 186 amyloid-positive (Aβ+) patients across the AD spectrum and 102 cognitively normal (CN) amyloid-negative (Aβ-) participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with baseline amyloid-PET, tau-PET and T1-weighted MRI. Longitudinal tau-PET and MRI (∼2 years) were available for a subset of 138 participants to assess the relationship between tau accumulation and WM atrophy over time. For replication, we included 378/60 CN Aβ+/Aβ- participants from the A4/LEARN cohort with baseline amyloid-PET, tau-PET and T1-weighted MRI, where a subset of 141/4 CN Aβ+/Aβ- subjects had ∼5-year longitudinal tau-PET and MRI. Cortical tau-PET standardized uptake value ratios were extracted from 210 cortical regions of the Brainnetome Atlas. In addition, we used a diffusion MRI-based tractography template to determine WM volumes of fibre tracts connected to cortical regions using segmented T1-weighted MRI. Using linear regression, we tested whether higher cortical tau-PET at baseline was associated with (i) lower baseline WM volume and (ii) faster WM volume loss over time, and (iii) whether faster longitudinal tau-PET increases paralleled faster WM loss. Testing the reverse model examined whether baseline WM atrophy predicted faster subsequent tau-PET increase in connected regions. Models were adjusted for age, sex, intracranial volume, WM hyperintensity volume, ApoE4 status and global amyloid-PET. In ADNI participants, elevated baseline cortical tau-PET in temporal regions was associated with lower baseline WM volume in adjacent regions, with more pronounced effects in patients across the AD spectrum and with weaker associations in the preclinical A4/LEARN sample. In both samples, higher baseline temporo-parietal tau-PET and faster tau-PET increase over time were significantly linked to accelerated volume loss in connected WM regions, which was especially pronounced in individuals on the AD spectrum. Importantly, baseline WM volume did not predict subsequent tau-PET rates of change in adjacent cortical regions, suggesting a unidirectional relationship between fibrillar tau and subsequent WM degeneration. Together, our findings suggest that cortical tau accumulation promotes atrophy in adjacent WM regions in AD, highlighting that tau-induced axonal degeneration and, potentially, neuronal disconnection might play a pivotal role in disease progression.
KW  - Humans
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: metabolism
KW  - Alzheimer Disease: diagnostic imaging
KW  - tau Proteins: metabolism
KW  - Male
KW  - Female
KW  - Aged
KW  - White Matter: pathology
KW  - White Matter: metabolism
KW  - White Matter: diagnostic imaging
KW  - Atrophy: pathology
KW  - Atrophy: metabolism
KW  - Positron-Emission Tomography
KW  - Aged, 80 and over
KW  - Magnetic Resonance Imaging
KW  - Cerebral Cortex: pathology
KW  - Cerebral Cortex: metabolism
KW  - Cerebral Cortex: diagnostic imaging
KW  - Middle Aged
KW  - Longitudinal Studies
KW  - Amyloid beta-Peptides: metabolism
KW  - Alzheimer’s disease (Other)
KW  - neuroimaging (Other)
KW  - progressive white matter degeneration (Other)
KW  - tau pathology (Other)
KW  - tau Proteins (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - MAPT protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40966722
DO  - DOI:10.1093/brain/awaf339
UR  - https://pub.dzne.de/record/282585
ER  -